According to a story from the CureDuchenne Blog, CureDuchenne founder and CEO Debra Miller announced that the organization has recently entered into a new partnership with the biotechnology company Myosana…
by Jodee Redmond from In The Cloud Copy Rich Horgan is the founder of the Boston-based biotech non-profit, Cure Rare Diseases. The 28-year-old decided to take action over concerns about…
CureDuchenne's Cares Sessions: Helping Connect and Inform Patient Families April 25th, 2020, 6:30 pm The Sessions program from CureDuchenne is geared specifically towards patients and their families as well as…
While genomic research presents the unique opportunity of combating diseases and gene malfunctions at the source, the practice has been incredibly controversial. Some people worry about the ethics of…
CureDuchenne Cares Workshops: Hear The Latest From Experts April 18th, 2020, 8:00 am The Workshops program from CureDuchenne are day-long educational events that are oriented towards caregivers and Duchenne muscular…
According to a study published in the journal Neurology, a measure called the vastus lateralis fat fraction was found to be useful in predicting the age at which a patient living…
CureDuchenne Cares Workshops: Hear The Latest From Experts April 4th, 2020, 8:00 am The Workshops program from CureDuchenne are day-long educational events that are oriented towards caregivers and Duchenne muscular…
According to a story from CureDuchenne, the biotechnology company Dyne Therapeutics recently announced that CureDuchenne Ventures has made an equity investment that will support the development of all new precision…
CureDuchenne's Cares Sessions: Helping Connect and Inform Patient Families March 28th, 2020, 6:30 pm The Sessions program from CureDuchenne is geared specifically towards patients and their families as well as…
CureDuchenne's Cares Sessions: Helping Connect and Inform Patient Families March 21st, 2020, 6:30 pm The Sessions program from CureDuchenne is geared specifically towards patients and their families as well as…
A Professional Course for Healthcare Providers This course meets all Montana Board of PT requirements for 6.5 CE hours and is approved by the Montana Board of OT Practice. The…
A recent editorial focusing on NMDs (neuromuscular disorders) was published in the journal Disease Models & Mechanisms. The editorial highlights a special issue of the journal devoted to building…
CureDuchenne Cares Workshops: Hear The Latest From Experts March 14th, 2020, 8:00 am The Workshops program from CureDuchenne are day-long educational events that are oriented towards caregivers and Duchenne muscular…
Shelley Simmonds recently attended the Festival of Genomics, the largest genomics event in the United Kingdom that is quickly growing into the biggest event in the world. It involves…
CureDuchenne's Cares Sessions: Helping Connect and Inform Patient Families March 7th, 2020, 6:30 pm The Sessions program from CureDuchenne is geared specifically towards patients and their families as well as…
.jpg)
Advances in medicine have been responsible for longer overall survival in patients with neurodegenerative-neuromuscular diseases. According to a recent report in RTMagazine, an increase in the number of patients…
CureDuchenne's Cares Sessions: Helping Connect and Inform Patient Families February 22nd, 2020, 6:30 pm The Sessions program from CureDuchenne is geared specifically towards patients and their families as well as…
Janet Woodcock, Director of the FDA’s Center for Drug Evaluation and Research (CDER) recently gave an interview to the publication FDA Voices about the agency’s approval in 2019 of a…
AskBio Asklepios BioPharmaceuticals (AskBio) was first founded in 2001. It is based out of North Carolina. This company is dedicated to the research of gene therapies as potential therapeutic options…
A Professional Course for Healthcare Providers This course has been verified by the Texas PT for 6.5 CCUs. The professional course is a valuable opportunity for caregivers and healthcare providers…
CureDuchenne Cares Workshops: Hear The Latest From Experts February 8th, 2020, 8:00 am The Workshops program from CureDuchenne are day-long educational events that are oriented towards caregivers and Duchenne muscular…
PTC Therapeutics is a pharmaceutical company that has been working with Translarna, a medication intended for the treatment of Duchenne muscular dystrophy (DMD). They analyzed this treatment and presented the…
CureDuchenne's Cares Sessions: Helping Connect and Inform Patient Families February 1st, 2020, 6:30 pm The Sessions program from CureDuchenne is geared specifically towards patients and their families as well as…
CureDuchenne's Cares Sessions: Helping Connect and Inform Patient Families January 11th, 2020, 6:30 pm The Sessions program from CureDuchenne is geared specifically towards patients and their families as well as…
According to a story from BioSpace, the US Food and Drug Administration (FDA) has recently approved the drug golodirsen (marketed as Vyondys 53) as a treatment for Duchenne muscular dystrophy…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
